The effect of ritanserin on dopamine (DA) re-uptake and efflux was studied in rat frontal cortex synaptosomes. When compared to other 5HT 2 receptor antagonists such as ketanserin and risperidone or DA D 2 receptor antagonists such as haloperidol and raclopride, the effect of ritanserin proved to be more potent. Ritanserin blocked the DA transporter with a K i of 0.18 ± 0.06 M, similar to cocaine (0.11 ± 0.005 M), while ketanserin had a K i of 0.93 ± 0.045; haloperidol of 2.07 ± 0.12; risperidone of 18.01 ± 0.62 and raclopride of 24.01 ± 1.55. In addition, 15 min from its local application to the synaptosomes, ritanserin potently released [ 3 ]H-DA leaving only 29.6 ± 1.6% of DA content, while ketanserin effect was equal to 46.5 ± 0.9%; haloperidol to 70.4 ± 2.2% and risperidone to 73.9 ± 1.5%, all tested at the dose of 10 M. Cocaine had no effect on DA efflux. These results suggest that ritanserin has a intrinsic dopaminergic effect which may help to explain its reported improvement on mood, cognition and negative symptoms of schizophrenia. Molecular Psychiatry (2000) 5, 673-677.
One of the most stimulating problems posed by atypical antipsychotics is to discover if their ability to act on the negative symptoms of schizophrenia relies on the same neurochemical profile that makes them unable to produce extrapyramidal symptoms (EPS). Such unique therapeutic ability has originally been attributed to their preferential effect on the mesolimbic rather than the nigrostriatal dopaminergic system. 1, 2 However, this explanation for the reduced EPS liability of atypical antipsychotics is equivocal since in vitro studies show that atypical antipsychotics exhibit identical receptor binding affinities for both mesolimbic and nigrostriatal D 2 receptors. 3 Alternatively, the higher affinity of clozapine for serotonin 5-HT 2 rather than the dopamine D 2 receptor 4 has received a great deal of attention, going as far as to suggest that the relative ratio of 5-HT 2 /D 2 binding affinity was essential for definition of the atypical abilities of an antipsychotic. 5 This was largely confirmed by the use of ritanserin, a piperidine derivative with very high affinity (K i = 0.30 nM) for all three 5-HT 2 receptor sites (5-HT 2A-2B-2C ), and a potency about 100-fold greater than that for the dopamine D 2 , the adrenoceptors ␣ 1 ␣ 2 and the serotonin 5-HT 1A receptors. 6 In a clinical pilot study, ritanserin was effective as an adjunctive therapy to haloperidol in alleviating EPS 7 or in improving negative symptoms 8 in schizophrenic patients undergoing longterm classical neuroleptic therapy.
Preclinical studies have since demonstrated that ritanserin stimulated the activity of midbrain dopaminergic cells 9 and systemic administration of this agent increased basal extracellular DA efflux in the medial prefrontal cortex and in the nucleus accumbens, 10, 11 which suggested the existence of an inhibitory tone of serotonin upon basal dopamine release in the mesolimbic system. However, contradictory data emerge from selective 5-HT 2 receptor antagonism on forebrain dopamine transmission, 12, 13 and on catalepsy, 14 both induced by neuroleptics. These results appear difficult to reconcile with only a simple model in which medial and dorsal raphe serotonergic neurons inhibit midbrain dopamine neuronal activity through a direct antagonism at receptors of the 5-HT 2 family.
Recently, ritanserin was reported to increase, in a dose-dependent manner, anxiety in simulated public speaking 15 and to increase craving in a tentative adjunct therapy to psychosocial treatment for cocaine dependence in humans, 16 suggesting a possible direct modulation of dopaminergic activity. The aim of the present experiments was to study whether ritanserin had an effect on targets other than its known 5-HT 2 antagonism, namely re-uptake or transport site for dopamine, being proposed as a mechanism of action of neuroleptics 17 or antidepressants, 18 by employing either binding techniques or rat brain synaptosomal preparations.
We found that ritanserin potently inhibited [ 3 H]-DA uptake in both frontal cortex and striatum (not shown) preparations, with similar affinity values (K i = 0.18 ± 0.06 and 0.20 ± 0.08 M, respectively). Representative dose-response curves of the percentage of [ 3 H]-DA uptake inhibition in the synaptosomes are shown in Figure 1 . The K i of ritanserin for [ 3 H]-DA uptake in the frontal cortex was similar to that of cocaine (0.11 ± 0.005 M) and about five-fold lower than that of its structurally closest compound ketanserine (0.93 ± 0.045 M). The classical neuroleptic, haloperidol, showed minor affinity (K i =2.07 ± 0.12 M) for the DA re-uptake site, and the atypical antipsychotics: clozapine, olanzapine and risperidone showed a very low affinity (K i =15.12 ± 0.41; 46.5 ± 1.41; and 18.01 ± 0.62 M, respectively) (see also Table 1 for a complete list of compounds tested).
When isolated frontal cortex synaptosomal fractions, preincubated with 50 nM [ 3 H]-DA, were challenged with different concentrations of ritanserin, we found that the lowest (0.5 M) concentration used did not affect the [ 3 H]-DA content whereas ritanserin at 1 M and 10 M emptied it by 19.5 ± 0.2% and 70.4 ± 0.5% respectively, demonstrating a dose-dependent effect on DA efflux as well. In this respect ritanserin was again more potent than 10 M ketanserine (53.5 ± 0.3%) and significantly more potent than 10 M cocaine (12 ± 0.7%); clozapine (12.01 ± 0.3%); haloperidol (29.6 ± 0.8%) and risperidone (26.1 ± 0.5%) (see Figure 2 and Table 2 ).
The present study shows that ritanserin exerts a specific effect on the dopamine re-uptake site with a blocking potency which is comparable to that of the Values are means ± SEM from three different assays. Newman-Keuls test for multiple comparisons after one-way ANOVA indicated a significant DA efflux from synaptosomes with respect to controls (**P Ͻ 0.001, *P Ͻ 0.05).
powerful psychostimulant cocaine. Re-uptake is a mechanism by which neurotransmitters are rapidly removed from the synaptic cleft and occurs through the action of specific transporter peptides which have been cloned and characterized. 19, 20 The re-uptake transporter functions in relation to a gradient pump, removing the monoamine from the most concentrated to the less concentrated side of the cellular membrane in order to prevent synaptic receptor overstimulation. However, if the monoamine accumulates in the presynaptic terminal and is not stored in the vesicles, as can be obtained with amphetamines and with the nonamphetamine stimulant amfonelic acid, the re-uptake mechanism will pump it out in the synapse. The mechanism by which ritanserin mediates dopamine efflux could be due to an action similar to that of amphetamine, 21 as it has recently been shown that local intracortical ritanserin application increases basal dopamine efflux in the rat medial prefrontal cortex, 11 and potentiates amphetamine-induced dopamine release. 22 This effect was hypothesized to be due to 5-HT 2 antagonism stimulating dopaminergic transmission but, if so, it should have occurred through 5-HT 2 receptors localized presynaptically in the medial prefrontal cortex, while they have been extensively demonstrated postsynaptically 23, 24 on GABA interneurons or on glutamatergic pyramidal neurons. 25, 26 A glutamatergic-ventral tegmental area circuit under the tonic control of 5-HT 2 receptors has been evoked to mediate this enhanced dopamine release after ritanserin but, to date, no evidence employing local infusion of 5-HT 2 receptor ligands and subsequent measurement of dopamine, GABA and glutamate has confirmed this theory.
Systemic administration of ritanserin was also reported to increase dopamine extracellular concentration in the nucleus accumbens, 10 and a recent study compared the in vivo regional effects of ritanserin with those of the atypical antipsychotics clozapine, risperidone and amperozide on the release of dopamine and serotonin in the rat brain. 27 Ritanserin and amperozide, which also block dopamine re-uptake, 26 were the only compounds which did not exert any major effect on dopamine metabolism in the nucleus accumbens and dorsal striatum. 25 The effect of ritanserin on dopamine re-uptake in rat striatal synaptosomes is in agreement with its reported antiparkinsonian activity in schizophrenic patients treated with classical neuroleptics. 7 Amperozide and ritanserin were also found to restore burst firing without affecting the mean firing rate of dopaminergic cells in the ventral tegmental area, where projections to the frontal cortex originate. 28 Ritanserin's effect on dopamine re-uptake in frontal cortex preparations may have important implications regarding the reported hypofrontality in chronic schizophrenic patients. It has been suggested that such hypofrontality may be associated with an impaired dopaminergic transmission clinically correlated to negative symptoms such as apathy, affective blunting, anhedonia and lack of drive and motivation. 29 In spite of the interesting data reported here there are a number of contentions that need to be addressed. Firstly, we Molecular Psychiatry have not measured direct binding of ritanserin to the dopamine transporter and therefore cannot conclude that it acts on the same site recognized by cocaine. It is also possible that ritanserin acts with two different mechanisms: one responsible for dopamine uptake inhibition, the other mediating the dopamine efflux. This is confirmed by the fact that potent dopamine uptake blockers (ie GBR 12909, mazindole, cocaine) do not have any effect on dopamine efflux. Ritanserin also binds with nM affinity to a number of receptors and interaction with these receptors may contribute to the effect observed on dopamine release. However, risperidone, which also interacts with the same type of receptors (except for a ෂ10-fold higher affinity for D 2 , ␣1 and ␣2)
30 is 100-fold less potent in blocking dopamine reuptake. Finally, ritanserin may also act by partially depleting monoamine stores as a consequence of tetrabenazine-like effect.
Continuing research with this compound can further dissect its specific serotonergic and dopaminergic effects which may imply a possible role as an efficacious antidepressant. It would moreover be interesting to test the hypothesis that other selective and potent 5-HT 2 antagonists exert a similar action on DAuptake in the frontal cortex. 
Materials and methods

Chemicals
Animals
Male Sprague-Dawley rats, 175-200 g, were purchased from Charles River (Como, Italy). Animals were housed three or four per cage and given free access to food and water under controlled conditions of temperature (22 ± 1°C) and humidity (65 ± 5%), with a 12 h light/dark cycle. In order to minimize pain and discomfort for the animals, all the experiments were carried out in accordance with the European Community's Council Directive of 24 November 1986 (86/609/EEC).
Tissue preparation
The animals were killed by decapitation and the frontal cortex was quickly dissected over ice and homogenized in 10 vol of 0.32 M sucrose containing 10 mM glucose and 10 mM Tris-HCl (pH 7.4). The homogenate was centrifuged at 1000 × g for 10 min and the resulting supernatant removed and centrifuged at 12 000 × g for 20 min to obtain a crude synaptosomal fraction (P2).
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Synaptosomal uptake and efflux of [
3 H]-DA The synaptosomes-containing pellet was resuspended in a modified Krebs-Henseleit buffer and assayed according to Schoemaker and Nickolson. 31 The standard uptake medium (pH 7.4 at 37°C) contained 140 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 10 mM glucose, 1.2 mM CaCl 2 , 10 mM hepes, 1 mM ascorbic acid, 0.054 mM EDTA, 0.1 mM pargyline.
Triplicate aliquots (90-150 g protein) of the P2 fraction were preincubated for 10 min at 37°C in the above mentioned buffer in the presence of fresh DMSO-dissolved drugs. Control samples contained an equal volume of DMSO. After preincubation the uptake was started by adding 50 nM of After incubation at 37°C for 5 min the uptake was stopped by filtering the samples through glass-fiber GF/C filters (previously soaked for 1 h in a 0.1% polyethyleneimine solution) and filters were washed three times with 0.9% NaCl. The values of [ 3 H]-DA uptake obtained from the synaptosomal fraction incubated at 4°C (blanks) were subtracted from the corresponding sample at 37°C. Inhibition curves were plotted and analyzed by computer with appropriate software (Kell 6.0, Biosoft, Cambridge, UK; Prism 3.0, Graph Software, San Diego, CA, USA).
For efflux experiments, after preincubation, P2 fractions were replenished with 50 nM of [ 3 H]-DA for 15 min and subsequently tested drugs were added to the media. Thereafter, samples were filtered at 30 and 40 min of incubation. Results are expressed both as the absolute [ 3 H]-DA content (pmol mg −1 protein) and as a percentage of the respective control values at 15 min.
The protein content was measured by Lowry's method using bovine serum albumin as standard.
